A Multi-Centre Double-Blind Randomised Placebo-Controlled Trial of Oral Anticoagulation in Systemic Sclerosis-Related Pulmonary Arterial Hypertension [ 2014 - 2018 ]

Also known as: A Clinical Trial of Anticoagulation in Scleroderma Heart-Lung Disease

Research Grant

[Cite as]

Researchers: Dr Mandana Nikpour (Principal investigator) ,  A/Pr David Prior A/Pr Peter Nash A/Pr Susanna Proudman Dr Jane Zochling
View all 10 related researchers

Brief description Scleroderma is an autoimmune disease that shortens life span by over 30 years. The main cause of death is pulmonary arterial hypertension (PAH), a condition of increased pressure in the lung vessels. Even in the era of 'advanced' PAH therapy, only 50% of patients are alive beyond 5 years. Formation of clots in the small blood vessels of the lung plays a major role in the development of PAH. In this clinical trial we aim to determine whether anticoagulation (treatment to prevent clotting) improves survival in scleroderma PAH.

Funding Amount $AUD 1,190,521.83

Funding Scheme Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]